Progress in the Research and Development of Anti-COVID-19 Drugs

Overview

Journal Front Public Health

Specialty Public Health

Date 2020 Aug 1

PMID 32733842

Citations 11

Authors

Lianzhou Huang

Yuanqiu Chen

Ji Xiao

Weisheng Luo

Feng Li

Yuan Wang

Yiliang Wang

Yifei Wang

Affiliations

Soon will be listed here.

Abstract

The outbreaks of COVID-19 due to SARS-CoV-2 has caused serious physical and psychological damage to global human health. COVID-19 spread rapidly around the world in a short time. Confronted with such a highly infectious respiratory disease, the research and development of anti-COVID-19 drugs became an urgent work due to the lack of specific drugs for the treatment of COVID-19. Nevertheless, several existing drugs are available to relieve the clinical symptoms of COVID-19. We reviewed information on selected anti-SARS-CoV-2 candidate therapeutic agents published until June 2, 2020. We also discussed the strategies of the development of anti-COVID-19 drugs in the future. Our review provides a novel insight into the future development of a safer, efficient, and toxic-less anti-COVID-19 drug.

Citing Articles

Polarimetric imaging for the detection of synthetic models of SARS-CoV-2: A proof of concept.

Gomez-Gonzalez E, Munoz O, Gomez-Martin J, Aceituno-Castro J, Fernandez-Munoz B, Navas-Garcia J J Quant Spectrosc Radiat Transf. 2023; 302:108567.

PMID: 36945203 PMC: 9987604. DOI: 10.1016/j.jqsrt.2023.108567.

Identifying Drug Candidates for COVID-19 with Large-Scale Drug Screening.

Wu Y, Pegan S, Crich D, Lou L, Mullininx L, Starling E Int J Mol Sci. 2023; 24(5).

PMID: 36901828 PMC: 10002104. DOI: 10.3390/ijms24054397.

Affinity binding of COVID-19 drug candidates (chloroquine/hydroxychloroquine) and serum albumin: Based on photochemistry and molecular docking.

Hu L, Yuan Y, Wen Z, Hu Y, Yin M, Hu Y J Photochem Photobiol B. 2023; 240:112667.

PMID: 36753782 PMC: 9893769. DOI: 10.1016/j.jphotobiol.2023.112667.

Spatiotemporal impact of non-pharmaceutical interventions against COVID-19 on the incidence of infectious diarrhea in Xi'an, China.

Zhang H, Shen L, Sun M, Zhao C, Li Q, Yang Z Front Public Health. 2022; 10:1011592.

PMID: 36518571 PMC: 9742410. DOI: 10.3389/fpubh.2022.1011592.

Localized delivery of nanomedicine and antibodies for combating COVID-19.

Tu B, Gao Y, An X, Wang H, Huang Y Acta Pharm Sin B. 2022; 13(5):1828-1846.

PMID: 36168329 PMC: 9502448. DOI: 10.1016/j.apsb.2022.09.011.

References

Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C . Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020; 179:104811. PMC: 7188648. DOI: 10.1016/j.antiviral.2020.104811. View

Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan A, Kamal M . Therapeutic management of patients with COVID-19: a systematic review. Infect Prev Pract. 2021; 2(3):100061. PMC: 7162768. DOI: 10.1016/j.infpip.2020.100061. View

Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K . Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020; 95:183-191. PMC: 7193136. DOI: 10.1016/j.ijid.2020.03.013. View

Scherholz M, Schlesinger N, Androulakis I . Chronopharmacology of glucocorticoids. Adv Drug Deliv Rev. 2019; 151-152:245-261. PMC: 6703983. DOI: 10.1016/j.addr.2019.02.004. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

Luan J, Lu Y, Jin X, Zhang L . Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020; 526(1):165-169. PMC: 7102515. DOI: 10.1016/j.bbrc.2020.03.047. View

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

Blaising J, Polyak S, Pecheur E . Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; 107:84-94. PMC: 7113885. DOI: 10.1016/j.antiviral.2014.04.006. View

10.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

11.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

12.

Han Q, Lin Q, Jin S, You L . Coronavirus 2019-nCoV: A brief perspective from the front line. J Infect. 2020; 80(4):373-377. PMC: 7102581. DOI: 10.1016/j.jinf.2020.02.010. View

13.

Trape J . The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001; 64(1-2 Suppl):12-7. DOI: 10.4269/ajtmh.2001.64.12. View

14.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

15.

Kumar S, Zhi K, Mukherji A, Gerth K . Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. Viruses. 2020; 12(5). PMC: 7290948. DOI: 10.3390/v12050486. View

16.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

17.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

18.

Sukumar N, Das S . Current trends in virtual high throughput screening using ligand-based and structure-based methods. Comb Chem High Throughput Screen. 2011; 14(10):872-88. DOI: 10.2174/138620711797537120. View

19.

Touret F, de Lamballerie X . Of chloroquine and COVID-19. Antiviral Res. 2020; 177:104762. PMC: 7132364. DOI: 10.1016/j.antiviral.2020.104762. View

20.

Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W . Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003; 349(5):507-8. DOI: 10.1056/NEJM200307313490519. View